Clinical ResearchQuality and OutcomeBeyond Medication Prescription as Performance Measures: Optimal Secondary Prevention Medication Dosing After Acute Myocardial Infarction
Key Words
Abbreviations and Acronyms
Cited by (0)
The TRIUMPH study was sponsored by a grant from the National Institutes of Health (National Heart, Lung, and Blood Institute): SCCOR Grant #P50HL077113. The PREMIER study (Prospective Registry Evaluating Myocardial Infarction: Events and Recovery) was principally supported by a grant from Cardiovascular Therapeutics, Inc., Palo Alto, California. The funding organizations did not play a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Dr. Spertus is supported by a Clinical and Translational Science Award (1UL1RR033179); discloses industry relationships with Lilly, Genentech, Amgen, EvaHeart, and Amorcyte; and has served on the United Healthcare Scientific Advisory Board. Dr. Masoudi discloses a contract with the American College of Cardiology Foundation. Dr. Daugherty is supported by a Career Development Grant Award (K08HL103776) from the National Heart, Lung, and Blood Institute. Dr. Maddox is supported by a Career Development Grant Award from the Veterans Affairs Health Services Research and Development Service. Dr. Chan is supported by a Career Development Grant Award (K23HL102224) from the National Heart, Lung, and Blood Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.